Washington—The ADA and American Association of Oral and Maxillofacial Surgeons told federal regulators that reclassification of hydrocodone-containing combination drug products “could cause inconvenience, unnecessary suffering and higher out-of-pocket costs for patients with a legitimate need” for the medications.
ADA, AAOMS recommend against controlled substance reclassification
Posted in Dental News.
rev="post-1383" No comments
– October 19, 2012
